Merck R&D Chief Confident on Expanding Pipeline towards Keytruda Patent Cliff and Beyond

Dean Y. Li, Executive Vice President, President, Merck Research Laboratories, Merck & Co. As the 2028 Keytruda (pembrolizumab) patent expiry looms large, US Merck is ratcheting up business development deals to weather an anticipated revenue cliff by diversifying its portfolio...read more